(Q44724905)

5 December 2017

title

Mycophenolate mofetil monotherapy in patients who underwent liver transplantation for hepatitis C cirrhosis (English)

1 reference

5 December 2017

0 references

liver transplantation

1 reference

A Manrique

1

1 reference

5 December 2017

C Jiménez

2

1 reference

5 December 2017

P Ortega

3

1 reference

5 December 2017

M Abradelo

4

1 reference

5 December 2017

A Gimeno

5

1 reference

5 December 2017

J Calvo

6

1 reference

5 December 2017

F Cambra

7

1 reference

5 December 2017

R L -Sterup

8

1 reference

5 December 2017

J M Morales

9

1 reference

5 December 2017

E Moreno

10

1 reference

5 December 2017

language of work or name

English

0 references

publication date

1 November 2008

1 reference

Transplantation Proceedings

5 December 2017

published in

1 reference

5 December 2017

volume

40

1 reference

5 December 2017

issue

9

1 reference

5 December 2017

page(s)

2962-2964

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.09.040

5 December 2017

1 reference

Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.09.040

Long-term improvement in renal function after cyclosporine reduction in renal transplant recipients with histologically proven chronic cyclosporine nephropathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.09.040

Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.09.040

Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.09.040

Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.09.040

Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin inhibitor-induced renal dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.09.040

Mycophenolate mofetil monotherapy in stable liver transplant patients with cyclosporine-induced renal impairment: a preliminary report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.09.040

Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.09.040

Mycophenolate mofetil monotherapy in liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.09.040

Mycophenolate mofetil can be used as monotherapy late after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.09.040

Mycophenolate mofetil monotherapy in liver transplant recipients: a single center experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.09.040

Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.09.040

Mycophenolate's influence in the treatment of recurrent hepatitis c following liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.09.040

Recurrence of hepatitis C in liver transplant recipients treated with mycophenolate mofetil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.09.040

Molecular mechanisms of action of ribavirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.09.040

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.TRANSPROCEED.2008.09.040

1 reference

5 December 2017

1 reference